ANGPTL2 increases bone metastasis of breast cancer cells through enhancing CXCR4 signaling

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Masuda, Tetsuro ^a   Endo, Motoyoshi ^a   Yamamoto, Yutaka ^b   Odagiri, Haruki ^a,c   Kadomatsu, Tsuyoshi ^a   Nakamura, Takayuki ^a   Tanoue, Hironori ^a   Ito, Hitoshi ^a   Yugami, Masaki ^a   Miyata, Keishi ^a   Morinaga, Jun ^a   Horiguchi, Haruki ^a   Motokawa, Ikuyo ^a   Terada, Kazutoyo ^a   Morioka, Masaki Suimye ^d   Manabe, Ichiro ^d   Iwase, Hirotaka ^a   Mizuta, Hiroshi ^a   Oike, Yuichi ^a,e  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; ANGPTL2 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CXCR4; COLLAGENASE 3; ETS1 PROTEIN, HUMAN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR ETS 1;

ANIMAL; ANTAGONISTS AND INHIBITORS; BONE TUMOR; BREAST TUMOR; CELL MOTION; CULTURE TECHNIQUE; FEMALE; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; SECONDARY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ANGIOPOIETINS; ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CXCL12; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 13; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTO-ONCOGENE PROTEIN C-ETS-1; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84940192849     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09170     Document Type: Article

References (53)

1. Hess, K. et al. Metastatic patterns in adenocarcinoma. Cancer 106, 1624-1633 (2006).
2. Siegel, R., Ma, J., Zou, Z., Jemal, A. Cancer statistics, 2014. CA Cancer J Clin 64, 9-29 (2014).
3. Pivot, X. et al. A retrospective study of first indicators of breast cancer recurrence. Oncology 58, 185-190 (2000).
4. Coleman, R. Skeletal complications ofmalignancy. Cancer 80, 1588-1594 (1997).
5. Kozlow, W., Guise, T. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 10, 169-180 (2005).
6. Zou, Y., Kottmann, A., Kuroda, M., Taniuchi, I., Littman, D. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393, 595-599 (1998).
7. Teicher, B., Fricker, S. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 16, 2927-2931 (2010).
8. Burger, J., Kipps, T. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107, 1761-1767 (2006).
9. Zhang, Z. et al. Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis. BMC Cancer 14, 1471-2407 (2014).
10. Chinni, S. et al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 66, 32-48 (2006).
11. Son, B. et al.Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 24, 1254-1264 (2006).
12. Tan, C. et al. CXCL12/CXCR4 promotes laryngeal and hypopharyngeal squamous cell carcinoma metastasis through MMP-13-dependent invasion via the ERK1/2/AP-1 pathway. Carcinogenesis 29, 1519-1527 (2008).
13. Yu, T. et al. CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway. Mol Cancer Res 9, 161-172 (2011).
14. Viguet-Carrin, S., Garnero, P., Delmas, P. The role of collagen in bone strength. Osteoporos Int 17, 319-336 (2006).
15. Odagiri, H. et al. The secreted protein ANGPTL2 promotes metastasis of osteosarcoma cells through integrin a5b1, p38 MAPK, and matrix metalloproteinases. Sci Signal 7, 2004612 (2014).
16. Muller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001).
17. Zlotnik, A., Burkhardt, A., Homey, B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 11, 597-606 (2011).
18. Kadomatsu, T., Endo, M., Miyata, K., Oike, Y. Diverse roles of ANGPTL2 in physiology and pathophysiology. Trends Endocrinol Metab 25, 245-254 (2014).
19. Tabata, M. et al. Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. Cell Metab 10, 178-188 (2009).
20. Horio, E. et al. Role of endothelial cell-derived angptl2 in vascular inflammation leading to endothelial dysfunction and atherosclerosis progression. Arterioscler Thromb Vasc Biol 34, 790-800 (2014).
21. Tazume, H. et al. Macrophage-derived angiopoietin-like protein 2 accelerates development of abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 32, 1400-1409 (2012).
22. Okada, T. et al. Synoviocyte-derived angiopoietin-like protein 2 contributes to synovial chronic inflammation in rheumatoid arthritis. Am J Pathol 176, 2309-2319 (2010).
23. Ogata, A. et al. The role of angiopoietin-like protein 2 in pathogenesis of dermatomyositis. Biochem Biophys Res Commun 418, 494-499 (2012).
24. Aoi, J. et al.Angiopoietin-like protein 2 is an important facilitator of inflammatory carcinogenesis and metastasis. Cancer Res 71, 7502-7512 (2011).
25. Aoi, J. et al. Angiopoietin-like protein 2 accelerates carcinogenesis by activating chronic inflammation and oxidative stress. Mol Cancer Res 12, 239-249 (2014).
26. Endo, M. et al. Tumor cell-derived angiopoietin-like protein ANGPTL2 is a critical driver of metastasis. Cancer Res 72, 1784-1794 (2012).
27. Endo, M. et al. Serum ANGPTL2 levels reflect clinical features of breast cancer patients: implications for the pathogenesis of breast cancer metastasis. Int J Biol Markers 27, 5000080 (2014).
28. Balkwill, F. Cancer and the chemokine network. Nat Rev Cancer 4, 540-550 (2004).
29. Ling, X. et al. The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo. PLoS One 8, 6 (2013).
30. Staller, P. et al. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425, 307-311 (2003).
31. Lee, B. et al. Carboxyl-terminal Src kinase homologous kinase negatively regulates the chemokine receptor CXCR4 through YY1 and impairs CXCR4/CXCL12 (SDF-1a)-mediated breast cancer cell migration. Cancer Res 65, 2840-2845 (2005).
32. Kukreja, P., Abdel-Mageed, A., Mondal, D., Liu, K., Agrawal, K. Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1a (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kB activation. Cancer Res 65, 9891-9898 (2005).
33. Phillips, R. et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1a. J Biol Chem 280, 22473-22481 (2005).
34. Maroni, P., Bendinelli, P., Matteucci, E. Desiderio, M. HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-kB. Carcinogenesis 28, 267-279 (2007).
35. Park, B. et al. An isoform of C/EBPb, LIP, regulates expression of the chemokine receptor CXCR4 and modulates breast cancer cell migration. J Biol Chem 288, 28656-28667 (2013).
36. Singareddy, R. et al. Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions. Mol Cancer Res 11, 1349-1361 (2013).
37. Zhang, C. et al. Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells. Nat Med 12, 240-245 (2006).
38. Lapidot, T., Kollet, O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia 16, 1992-2003 (2002).
39. Mukherjee, D.& Zhao, J. The Role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res 3, 46-57 (2013).
40. Wei, G. et al. Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis. Blood 114, 1123-1130 (2009).
41. Iwasaka, C., Tanaka, K., Abe, M., Y, S. Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J Cell Physiol 169, 522-531 (1996).
42. Zhan, Y. et al. Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest 115, 2508-2516 (2005).
43. Geisinger, M. et al. Ets-1 is essential for connective tissue growth factor (CTGF/CCN2) induction by TGF-b1 in osteoblasts. PLoS One 7, 23 (2012).
44. Zhang, B. et al. Tumor-derived matrixmetalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer. BMC Cancer 8, 1471-2407 (2008).
45. Kominsky, S., Doucet, M., Thorpe, M.,Weber, K. MMP-13 is over-expressed in renal cell carcinoma bone metastasis and is induced by TGF-b1. Clin Exp Metastasis 25, 865-870 (2008).
46. Hsu, C., Shen, G., Ko, J. Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer. Lung Cancer 52, 349-357 (2006).
47. Leeman, M., McKay, J., Murray, G. Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol 55, 758-762 (2002).
48. Shah, M. et al. An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer. PLoS One 7, 11 (2012).
49. Nannuru, K. et al. Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-b signaling at the tumor-bone interface. Cancer Res 70, 3494-3504 (2010).
50. Trapnell, C., Pachter, L., Salzberg, S. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111 (2009).
51. Quinlan, A.,Hall, I. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841-842 (2010).
52. Audic, S. Claverie, J. The significance of digital gene expression profiles. Genome Res 7, 986-995 (1997).
53. Yamamoto, Y. et al. Hypoxia-inducible factor 1a is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat 110, 465-475 (2008).